| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2010: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
|
|---|
| Research Abstract |
To explore a novel therapy against Parkinson disease, we evaluated the therapeutic effects of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) in 6-OHDA induced Parkinson disease model rats. Intravenous administration of hBM-MSCs inhibited methamphetamine-stimulated rotational behevior at 7, 14, 21 and 28 days after transplantation. Rats injected with hBM-MSCs displayed significant preservation of tyrosine hydroxylase (TH)-positive fibers in the striatum and the number of TH-positive neurons in the substantia nigra compacta (SNpc). In contrast, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba1) was markedly inhibited by intravenous admnistration of hBM-MSCs. The findings that hBM-MSCs attenuate 6-OHDA-induced dopaminergic neurodegeneration and glial activation raise the possibility that hBM-MSCs could be a novel therapeutic option to prevent Parkinson disease development.
|
